Brought to you by 
NanoString takes an option to exclusively license a liver cancer gene signature from the Broad Institute
30 Apr 2013
Executive Summary
The Broad Institute has granted life sciences company NanoString Technologies Inc. an option to license exclusive worldwide rights to a 186-gene signature that could be used to determine the prognosis of patients with hepatocellular carcinoma (HCC) or hepatitis C-related early-stage cirrhosis.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NanoString takes an option to exclusively license a liver cancer gene signature from the Broad Institute
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice